Holen Sie sich die Stockscreener-App
3.56
2.89%
0.10
Schlusskurs vom Vortag:
$3.46
Offen:
$3.57
24-Stunden-Volumen:
4.89M
Relative Volume:
3.49
Marktkapitalisierung:
$841.00M
Einnahmen:
$4.90M
Nettoeinkommen (Verlust:
$-399.99M
KGV:
-1.2532
EPS:
-2.8407
Netto-Cashflow:
$-122.90M
1W Leistung:
+5.64%
1M Leistung:
-26.75%
6M Leistung:
-34.92%
1J Leistung:
-43.49%
1-Tages-Spanne:
$3.46
$3.64
1-Wochen-Bereich:
$3.21
$3.925
52-Wochen-Spanne:
$3.105
$7.9825
Inventiva Adr Stock (IVA) Company Profile
Compare IVA vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IVA
Inventiva Adr
|
3.56 | 796.11M | 4.90M | -399.99M | -122.90M | -2.8407 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inventiva Adr Stock (IVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-19 | Eingeleitet | Truist | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-12 | Eingeleitet | Leerink Partners | Outperform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-06 | Eingeleitet | Wolfe Research | Outperform |
| 2025-09-03 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-27 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-21 | Eingeleitet | TD Cowen | Buy |
| 2024-11-12 | Eingeleitet | UBS | Neutral |
| 2023-10-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-05-31 | Eingeleitet | ROTH MKM | Buy |
| 2023-05-19 | Hochstufung | Societe Generale | Sell → Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2022-11-15 | Herabstufung | Societe Generale | Buy → Sell |
| 2021-03-08 | Herabstufung | Societe Generale | Buy → Sell |
| 2020-08-05 | Eingeleitet | ROTH Capital | Buy |
| 2020-08-04 | Eingeleitet | Guggenheim | Buy |
| 2020-08-04 | Eingeleitet | Stifel | Buy |
Alle ansehen
Inventiva Adr Aktie (IVA) Neueste Nachrichten
Price to earnings forward of Inventiva SA ADR – HAN:6IVA - TradingView
IVA - Finviz
CapEx per share of Inventiva SA ADR – HAM:6IVA - TradingView
AIkido Pharma Inc. (AIKI) Peer Comparison – Compare with Others - Value Research
6IVA Stock Price and Chart — HAM:6IVA - TradingView
CinCor Pharma Inc (CINC) Peer Comparison – Compare with Others - Value Research
Jupiter Neurosciences, Inc. Warrants (JUNSW) Peer Comparison – Compare with Others - Value Research
Biophytis (BPTS) Peer Comparison – Compare with Others - Value Research
Entasis Therapeutics Holdings Inc. (ETTX) Peer Comparison – Compare with Others - Value Research
IVA News | INVENTIVA SAADR (NASDAQ:IVA) - ChartMill
IVA Price History for Inventiva S.A. ADR Stock - Barchart.com
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Average Rating of "Buy" by Brokerages - MarketBeat
Inventiva S.A. Sponsored ADR $IVA Stake Reduced by Ally Bridge Group NY LLC - MarketBeat
Inventiva (IVA) Short Interest & Short Float | Updated Jul 2026 $IVA - MarketBeat
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Cantor Fitzgerald Initiates Inventiva SA ADR at Overweight - Moomoo
Inventiva (IVA) Announces Issuance of New EIB Warrants, Completes EIB Warrant Restructuring - Yahoo Finance
After plunging 30.8% in 4 weeks, here's why the trend might reverse for Inventiva (IVA) - MSN
Down 31.8% in 4 weeks, here's why Inventiva (IVA) looks ripe for a turnaround - MSN
6IVA Forecast — Price Target — Prediction for 2027 - TradingView
Inventiva S.A. (IVA) is One of the Best Stocks Under $10 Offering More Than 50% Upside - Yahoo Finance
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA) - Yahoo Finance
A2P796 Forecast — Price Target — Prediction for 2027 - TradingView
Inventiva SA ADR Actuals & Estimates (LSX:A2P796) - TradingView
Inventiva SA ADR Actuals & Estimates (LS:A2P796) - TradingView
Inventiva SA ADR Actuals & Estimates (NASDAQ:IVA) - TradingView
Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development - GlobeNewswire Inc.
Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround - Yahoo Finance
Super Micro Computer, Summit Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
IVA SEC FilingsInventiva S.A. 10-K, 10-Q, 8-K Forms - Stock Titan
Here's Why Inventiva (IVA) Is a Great 'Buy the Bottom' Stock Now - MSN
Assessing Inventiva (ENXTPA:IVA) Valuation As Losses Deepen And MASH Trial Progresses - Yahoo Finance
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Phreesia, Service Properties Trust, Inventiva and other big stocks moving lower in Tuesday's pre-market session - MSN
Inventiva (NASDAQ:IVA) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Phreesia, Service Properties Trust, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Update - MarketBeat
Zenas Biopharma, Daqo New Energy and other big stocks moving lower in Friday's pre-market session - MSN
Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives $17.00 Consensus PT from Brokerages - Defense World
Short Interest in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Drops By 20.4% - MarketBeat
Does Inventiva (IVA) Have the Potential to Rally 136.34% as Wall Street Analysts Expect? - Yahoo Finance
Inventiva CEO: Phase 3 Lanifibranor MASH Trial Fully Enrolled, Top-Line Data Due in H2 - Yahoo Finance
Finanzdaten der Inventiva Adr-Aktie (IVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):